MENU

Integral Diagnostics Ltd reports: Underlying NPAT up 22.7%

Integral Diagnostics Ltd (ASX: IDX) reported its half-year result to 31 December 2017 today.

Integral Diagnostics is one of the larger radiology businesses on the ASX. Here are some of the highlights from its report compared to the prior corresponding period to 31 December 2016:

  • Operating revenue up 5.8% to $92.8 million
  • Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) up 12.4% to $19 million
  • Underlying earnings before interest and tax (EBIT) up 17.6% to $14 million
  • Underlying net profit after tax (NPAT) up 22.7% to $9.2 million
  • Free cash flow increased by 70.2% to $17.7 million.
  • Cash and cash equivalents increased by $4 million.

Underlying profit is the best measure of performance because the statutory performance includes one-off acquisition costs.

Management believe that the long-term drivers remain for the business. A number of Medicare and government changes means that the business’ future is rosier than before.

The ageing population of Australia will also be a very positive tailwind for the business over the coming years.

The business expects that normalised FY18 NPAT for the whole year will come in at around 20%, this prediction excludes the takeover costs.

Management expect to deliver revenue growth stronger than previously expected, better cost efficiency initiatives, a lower effective tax rate and lower capital spending due to economies of scale.

The board also gave an update about the takeover offer from Capitol Health Ltd (ASX: CAJ). The board re-iterated that shareholders should do nothing until they have read Integral Diagnostics’ target’s statement, which will be provided no more than 15 days after Capital Health has dispatched its bidder’s statement. The target’s statement will contain the Board’s recommendation.

Capitol may bid a higher amount for Integral, but I wouldn’t buy shares just for that purpose.

Instead, I’d rather buy shares of these exciting growth stocks.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.